Artemis Medicare Services Ltd logo

Artemis Medicare Services Ltd

ARTEMISMED NSE

Key Fundamentals

MicrocapHospitalsHealthcare Services
Market Cap
₹4,911 Cr
Volatility
Moderate
P/E Ratio
42.13
EBITDA
₹218 Cr
Return on Equity
11.03%
Debt to Equity
0.28
Book Value
₹54.69
EPS
₹4.07
52W High
₹325.9
52W Low
₹203.35

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Artemis Medicare Services Ltd insights

36 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has delivered good profit growth of 75.6% CAGR over last 5 years

Weaknesses

3
  • Stock is trading at 5.26 times its book value
  • Company has a low return on equity of 12.1% over last 3 years.
  • Promoter holding has decreased over last 3 years: -9.64%

Growth Rate

Revenue Growth
14.56% ↗
Net Income Growth
26.16% ↗
Cash Flow Change
-15.25% ↘
ROE
13.24% ↗
ROCE
12.02% ↗
EBITDA Margin (Avg.)
2.99% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 18d ago
AI opinion · based on fundamentals
Risk medium

Artemis Medicare Services Ltd is a mid-cap hospital chain with a market cap of ₹4,786 Cr, trading at a PE of 46.2x and PB of 5.54x. The company has delivered strong profit growth of 76% CAGR over 5 years on sales growth of 21% CAGR, though ROE remains modest at 12% and promoter holding has declined by 9.64% over three years.

Bull Case 7
  • Exceptional 5-year compounded profit growth of 76% CAGR indicates strong operating leverage and margin expansion
  • TTM revenue growth of 16% shows continued top-line momentum even on a larger base
  • TTM profit growth of 27% outpaces revenue growth of 16%, suggesting continued margin improvement
  • 5-year compounded sales growth of 21% demonstrates consistent demand for healthcare services
  • 3-year profit CAGR of 40% reflects sustained earnings acceleration beyond a one-time post-COVID bounce
  • Stock has delivered 52% CAGR over 5 years and 26% over 1 year, indicating sustained investor confidence
  • 10-year compounded sales growth of 10% shows a long track record of steady revenue expansion
Bear Case 7
  • PE of 46.2x is elevated relative to the 12% ROE, implying the market is pricing in growth that may not materialize
  • Price-to-book of 5.54x leaves limited margin of safety if growth decelerates
  • Return on equity of 12% over 3 years is modest for a company commanding such premium valuations
  • Promoter holding has decreased by 9.64% over the last 3 years, raising questions about insider confidence
  • Dividend yield of just 0.15% offers negligible income support to shareholders
  • 10-year profit CAGR of only 17% versus 5-year CAGR of 76% suggests much of the earnings surge is recent and may not be sustainable
  • 10-year ROE average of 10% indicates historically modest capital efficiency despite recent improvement to 12%

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 16d ago
Positives 3
  • Fund raise approved overwhelmingly Jul 20

    Shareholders approved raising funds via equity shares with 98.68% votes in favour, signaling strong investor confidence and capital for growth.

  • BRSR filed for FY2025-26 Jul 7

    Artemis Medicare submitted its Business Responsibility and Sustainability Report for FY2025-26, disclosing ESG metrics, energy consumption, and sustainability initiatives.

  • AGM with dividend and governance Jul 7

    22nd AGM scheduled for July 31, 2026 with final dividend of Re. 0.45/share, auditor reappointment, and two new Independent Director appointments.

Neutral 1
  • Q1 FY27 earnings call Aug 4 Jul 29

    Artemis Medicare scheduled Q1 FY27 earnings conference call on August 4, 2026 at 11:00 AM IST, hosted by Anand Rathi Research with MD, CFO, and IR Head participating.

TL;DR: Artemis Medicare is in a stable governance phase with no visible headwinds. The near-unanimous equity raise approval provides growth capital, while ESG disclosures and board refreshment reflect maturing corporate governance. The upcoming Q1 FY27 earnings call on Aug 4 will be the next catalyst to watch for operational performance signals.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
201
217
210
217
217
235
227
235
250
270
267
274
282
Expenses
174
184
179
181
181
193
190
199
209
220
223
224
227
Operating Profit
27
33
32
36
36
42
37
36
41
50
44
50
55
OPM %
14%
15%
15%
17%
16%
18%
16%
15%
16%
19%
16%
18%
20%
Other Income
1
2
2
2
4
8
9
12
7
8
4
8
5
Interest
6
7
8
8
8
8
8
8
7
7
7
6
6
Depreciation
9
9
10
10
10
11
11
11
11
11
12
12
12
PBT
13
19
16
19
22
31
27
29
30
40
30
39
42
Tax %
26%
27%
29%
28%
24%
27%
23%
20%
29%
25%
24%
25%
26%
Net Profit
10
14
12
14
17
23
21
23
21
30
23
30
31
EPS in Rs
0.73
1.01
0.85
1.02
1.24
1.64
1.51
1.69
1.54
2.16
1.42
1.87
1.96
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
368
402
459
503
547
563
402
545
714
845
913
1,060
1,093
Expenses
325
359
406
442
480
501
367
477
620
717
763
875
893
Operating Profit
43
43
53
60
66
62
35
68
94
128
150
185
200
OPM %
12%
11%
11%
12%
12%
11%
9%
12%
13%
15%
16%
17%
18%
Other Income
3
5
4
3
2
4
7
3
7
7
33
27
25
Interest
12
9
9
9
11
13
12
11
19
30
30
27
26
Depreciation
12
12
15
18
20
22
21
21
29
38
43
46
48
PBT
21
27
32
35
37
32
9
39
53
68
109
139
151
Tax %
12%
21%
16%
24%
44%
36%
20%
16%
25%
28%
24%
25%
—
Net Profit
19
22
27
27
21
20
7
33
40
49
83
103
113
EPS in Rs
0.88
1.03
1.29
1.27
0.98
1.54
0.54
2.46
2.96
3.62
6.07
6.53
7.41
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
15%
12%
7%
7%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
21
21
21
21
0
13
13
13
13
14
14
16
Reserves
135
163
183
210
280
301
308
348
393
438
828
923
Borrowings
85
68
94
91
114
108
137
190
268
305
280
260
Other Liabilities
90
93
124
130
160
159
130
145
207
191
221
225
Total Liabilities
331
345
422
452
555
581
589
697
882
948
1,343
1,424
Fixed Assets
239
249
283
309
381
387
372
476
584
699
729
790
CWIP
0
1
27
43
49
56
81
64
95
33
40
33
Investments
0
0
0
0
0
2
4
6
12
15
15
15
Other Assets
91
94
112
100
124
137
132
152
192
200
559
585
Total Assets
331
345
422
452
555
581
589
697
882
948
1,343
1,424
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
53
20
58
72
41
56
27
61
129
108
150
129
Investing
-10
-14
-74
-67
-50
-22
-34
-106
-153
-90
-396
-96
Financing
-35
-24
19
-10
14
-33
12
44
30
-26
274
-41
Net Cash Flow
7
-18
3
-4
5
2
6
-2
7
-8
28
-8
Free Cash Flow
37
4
-17
11
-17
37
2
-45
-5
36
57
25
CFO/OP
127
48
112
121
76
97
71
114
140
95
109
81
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
39
49
48
40
52
50
48
47
43
36
37
38
Inventory Days
26
21
19
—
—
—
—
—
—
—
—
—
Days Payable
195
189
187
—
—
—
—
—
—
—
—
—
Cash Conversion Cycle
-129
-120
-120
40
52
50
48
47
43
36
37
38
Working Capital Days
-59
-31
-44
-53
-51
-36
-36
-25
-45
-29
-31
-19
ROCE %
14%
15%
16%
15%
14%
11%
4%
10%
11%
14%
15%
15%

Shareholding Pattern

As of Jun 2026
Promoters 58.39%
Public 12.79%
FIIs 12.29%
Others 7.97%
Government 6.16%
DIIs 2.40%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Nov 2025Dec 2025Mar 2026Jun 2026
Promoters
69.82%
69.82%
69.82%
69.82%
69.82%
69.59%
69.27%
68.92%
68.92%
68.03%
68.03%
68.03%
68.03%
67.51%
67.17%
67.17%
67.17%
66.53%
66.53%
58.43%
58.39%
58.39%
58.39%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.09%
0.00%
0.10%
0.16%
0.22%
0.64%
0.31%
0.24%
0.37%
12.48%
12.47%
12.19%
12.29%
DIIs
0.91%
0.91%
0.91%
0.91%
0.91%
0.91%
0.90%
1.15%
1.38%
1.41%
1.52%
1.20%
2.61%
3.45%
3.60%
4.50%
5.04%
4.76%
4.27%
3.35%
2.91%
2.89%
2.40%
Government
7.36%
7.36%
7.36%
7.36%
7.36%
7.34%
7.31%
7.27%
7.27%
7.18%
7.18%
7.18%
7.18%
7.12%
7.09%
7.09%
7.09%
7.02%
7.02%
6.16%
6.16%
6.16%
6.16%
Public
10.31%
14.18%
14.68%
15.21%
15.24%
16.82%
16.39%
16.33%
16.21%
15.51%
15.53%
15.20%
14.74%
14.23%
13.89%
12.76%
12.86%
12.93%
13.44%
11.65%
12.12%
12.36%
12.79%
Others
11.59%
7.72%
7.22%
6.69%
6.66%
5.35%
6.13%
6.32%
6.23%
7.87%
7.65%
8.39%
7.34%
7.53%
8.03%
7.84%
7.53%
8.52%
8.37%
7.93%
7.96%
8.01%
7.97%
No. of Shareholders
0
5,273
6,010
10,765
12,827
12,098
15,177
14,637
18,100
19,082
20,529
22,375
19,993
19,795
26,054
27,003
28,397
31,614
33,559
31,884
31,602
32,044
36,335

Documents

Frequently Asked Questions about Artemis Medicare Services Ltd

What does Artemis Medicare Services Ltd do?
Artemis Medicare Services Ltd (AMSL) was incorporated in 2004, operates a 541-bedded multi-specialty tertiary care hospital in Gurgaon. [1][2]
Where is Artemis Medicare Services Ltd (ARTEMISMED) listed?
Artemis Medicare Services Ltd is listed on the Indian stock exchanges. It is listed on NSE: ARTEMISMED and BSE: 542919. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Artemis Medicare Services Ltd belong to?
Artemis Medicare Services Ltd operates in the Healthcare Services sector within the Hospitals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Artemis Medicare Services Ltd?
Artemis Medicare Services Ltd has a market capitalisation of approximately ₹4910.66 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Artemis Medicare Services Ltd?
The Price-to-Earnings (PE) ratio of Artemis Medicare Services Ltd is 42.13. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Artemis Medicare Services Ltd?
Over the past 52 weeks, Artemis Medicare Services Ltd has traded between a low of ₹203.35 and a high of ₹325.9. This range helps investors understand the stock's price volatility and recent trading levels.
Does Artemis Medicare Services Ltd pay dividends?
Yes, Artemis Medicare Services Ltd has a dividend yield of 0.14%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Artemis Medicare Services Ltd?
Artemis Medicare Services Ltd has a Return on Equity (ROE) of 11.03%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Artemis Medicare Services Ltd on Tapetide?
On Tapetide, you can view Artemis Medicare Services Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Artemis Medicare Services Ltd (AMSL) was incorporated in 2004, operates a 541-bedded multi-specialty tertiary care hospital in Gurgaon. [1][2]

Website artemishospitals.com
CEO Dr. Devlina Chakravarty DMRD, DNB, M.D., Radiology
Employees 2,077
Listed 2020-01-23
Face Value ₹ 1
Issued Size 15,83,06,247

Explore More

More in Healthcare Services → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List